Viking Therapeutics, Inc. VKTX
At closeNov 3, 2026, 7:53 PM EST
After hours · Nov 3, 7:53 PM ET
- YTD
- -25.84%
- 1 year
- -27.53%
- Market cap
- 3.33B
- EPS (ttm)
- -5.42
- Shares out
- 127.52M
- Forward P/E
- -5.09
- YTD return
- -25.84%
- 1-year return
- -27.53%
- Volume
- 2.74M
- Avg volume
- 4.84M
- Open
- 26.88
- Previous close
- 26.83
- Day's range
- 25.99 – 27.58
- 52-week range
- 23.82 – 43.15
- Beta
- 0.75
- Analysts
- Strong Buy
- Price target
- 95.32 (+265.3%)
- Earnings date
- Feb 10, 2027
2Y -37.05 (-58.68%)
Key statistics
- Enterprise value
- 2.72B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 5.65
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -237.78M
- Total cash
- 959.81M
- Total debt
- 254.69M
- Return on equity
- -96.37%
- Short % of float
- 21.06%
- 50-day average
- 30.37
- 200-day average
- 32.38
Analyst view
Consensus: strong buy
- Target (low)
- 34.00
- Target (mean)
- 95.32
- Target (high)
- 125.00
- Strong buy5
- Buy14
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 10, 2027
Expected Feb 10, 2027. Consensus EPS estimate -1.35.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2027 | Dec 30, 2026 | -1.38 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | -1.06 | -1.55 | -0.49 | -46.23% |
| Jul 29, 2026 | Jun 30, 2026 | -1.23 | -1.10 | +0.13 | +10.57% |
| Apr 29, 2026 | Mar 31, 2026 | -1.01 | -1.37 | -0.36 | -35.64% |
| Feb 11, 2026 | Dec 31, 2025 | -0.89 | -1.38 | -0.49 | -55.06% |
| Oct 22, 2025 | Sep 30, 2025 | -0.70 | -0.81 | -0.11 | -15.71% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 20, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 15, 2026 | UBS | init | — | Buy |
| Oct 7, 2026 | Truist Securities | main | Buy | Buy |
| Sep 23, 2026 | Truist Securities | main | Buy | Buy |
| Aug 11, 2026 | JP Morgan | main | Overweight | Overweight |
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vikingtherapeutics.com
News
Viking Therapeutics to Participate at Upcoming Investor Conferences 
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case. 
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118 
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach? 
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet 
Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet) 
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses 
VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress 
Viking Therapeutics Stock Jumps: What's Going On? 
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
Your note
Sign in to keep a note on VKTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AUBUCHON NEIL WILLIAM | Officer | Purchase | Mar 9, 2026 | 4,475 |
| FOEHR MATTHEW W | Director | Stock Award(Grant) | Jan 1, 2026 | 135,186 |
| KELLY-GEMMELL DOROTHY ELIZABETH | Director | Stock Award(Grant) | Jul 30, 2026 | 6,333 |
| LIAN BRIAN | Chief Executive Officer | Sale | Jul 28, 2026 | 2,572,440 |
| MACARTNEY LAWSON | Director | Stock Award(Grant) | Jan 1, 2026 | 51,115 |
| MANCINI MARIANNA | Chief Operating Officer | Sale | Jul 28, 2026 | 422,760 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 4.97% | 6,335,756 | 165.30M | Jun 29, 2026 |
| Blackrock Inc. | 4.85% | 6,189,649 | 161.49M | Jun 29, 2026 |
| State Street Corporation | 4.40% | 5,606,394 | 146.27M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.96% | 5,053,663 | 131.85M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.52% | 4,484,263 | 116.99M | Jun 29, 2026 |
| Two Sigma Investments, LP | 3.09% | 3,937,414 | 102.73M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.74% | 3,500,175 | 91.32M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.70% | 3,444,940 | 89.88M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.98% | 2,528,235 | 65.96M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.14% | 1,458,461 | 38.05M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.05% | 1,333,178 | 34.78M | Jun 29, 2026 |
| American Century Mutual Funds, Inc.-HERITAGE FUND | 1.04% | 1,331,574 | 34.74M | Jul 30, 2026 |